Katherine Yun1, Kailey Urban1, Blain Mamo1, Jasmine Matheson1, Colleen Payton1, Kevin C Scott1, Lihai Song1, William M Stauffer1, Barbara L Stone1, Janine Young1, Henry Lin1. 1. At the time the work was conducted, Katherine Yun was with PolicyLab, Division of General Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, and Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Kailey Urban and Blain Mamo were with the Refugee Health Program, Minnesota Department of Health, Saint Paul. Jasmine Matheson was with the Refugee Health Program, Washington State Department of Health, Shoreline. Colleen Payton and Kevin C. Scott were with Family and Community Medicine, Thomas Jefferson University, Philadelphia, PA. Lihai Song was with the Healthcare Analytics Unit, Center for Pediatric Clinical Effectiveness, and PolicyLab, The Children's Hospital of Philadelphia. William M. Stauffer was with the Departments of Medicine and Pediatrics, University of Minnesota, Minneapolis. Barbara L. Stone was with the Refugee Health Program, Colorado Department of Public Health and Environment, Denver. Janine Young was with General Pediatrics, Denver Health and Hospitals, Denver, CO. Henry Lin was with the Division of Gastroenterology, The Children's Hospital of Philadelphia.
Abstract
OBJECTIVES: To determine whether the addition of hepatitis B virus (HBV) vaccine to national immunization programs improved vaccination rates among refugee children, a marginalized population with limited access to care. METHODS: The sample included 2291 refugees younger than 19 years who completed HBV screening after arrival in the United States. Children were categorized by having been born before or after the addition of the 3-dose HBV vaccine to their birth country's national immunization program. The outcome was serological evidence of immunization. RESULTS: The odds of serological evidence of HBV immunization were higher for children born after the addition of HBV vaccine to their birth country's national immunization program (adjusted odds ratio = 2.54; 95% confidence interval = 2.04, 3.15). CONCLUSIONS: National HBV vaccination programs have contributed to the increase in HBV vaccination coverage observed among US-bound refugee children. PUBLIC HEALTH IMPLICATIONS: Ongoing public health surveillance is needed to ensure that vaccine rates are sustained among diverse, conflict-affected, displaced populations.
OBJECTIVES: To determine whether the addition of hepatitis B virus (HBV) vaccine to national immunization programs improved vaccination rates among refugee children, a marginalized population with limited access to care. METHODS: The sample included 2291 refugees younger than 19 years who completed HBV screening after arrival in the United States. Children were categorized by having been born before or after the addition of the 3-dose HBV vaccine to their birth country's national immunization program. The outcome was serological evidence of immunization. RESULTS: The odds of serological evidence of HBV immunization were higher for children born after the addition of HBV vaccine to their birth country's national immunization program (adjusted odds ratio = 2.54; 95% confidence interval = 2.04, 3.15). CONCLUSIONS: National HBV vaccination programs have contributed to the increase in HBV vaccination coverage observed among US-bound refugee children. PUBLIC HEALTH IMPLICATIONS: Ongoing public health surveillance is needed to ensure that vaccine rates are sustained among diverse, conflict-affected, displaced populations.
Authors: Katherine Yun; Jasmine Matheson; Colleen Payton; Kevin C Scott; Barbara L Stone; Lihai Song; William M Stauffer; Kailey Urban; Janine Young; Blain Mamo Journal: Am J Public Health Date: 2015-11-12 Impact factor: 9.308
Authors: Carmine Rossi; Ian Shrier; Lee Marshall; Sonya Cnossen; Kevin Schwartzman; Marina B Klein; Guido Schwarzer; Chris Greenaway Journal: PLoS One Date: 2012-09-05 Impact factor: 3.240
Authors: Ales Janda; Kristin Eder; Roland Fressle; Anne Geweniger; Natalie Diffloth; Maximilian Heeg; Nadine Binder; Ana-Gabriela Sitaru; Jan Rohr; Philipp Henneke; Markus Hufnagel; Roland Elling Journal: PLoS Med Date: 2020-03-31 Impact factor: 11.069